June 28, 2021 6:06pm
It’s the investor against the “machine” with a bit of complacency in today’s sector as Biostage (BSTG) continues to “pump” its way-out from delisting
Pre-open indications: 7 HITs and 1 MISS
My comments try to distinguish the temporary from real pricing digression or progress.
If you’re looking for sector intel, ideas and facts or numbers (which don’t lie) in a volatile climate, RMi defines the rigors of share pricing! My comments distinguish the temporary from real pricing digression or progress.
Subscription is coming in July, it’s not conscription but, an offer to join our collective of like-minded investors!
The Dow closed DOWN -150.57 points (-0.44%); the S&P closed UP +9.91 points (0.23%) while the Nasdaq closed UP +140.12 points (+0.98%)
Henry’omics:
The U.S. stock market struggled for direction on Monday, but a moderate start for stem, cell and gene therapy equities as the Nasdaq pushed to another record high.
“Stocks finished their best week in months on Friday as investors are growing more confident the current inflation in the U.S. is not a sustained economic threat, but a temporary uptick.” <CNBC>
traders looked ahead to more key economic data later this week.
Intellia Therapeutics (NTLA) Proposes $400 M Public Offering. NTLA closed up +$44.60 or +50.21% after researchers tested a single dose of gene-editing treatment in patients with transthyretin amyloidosis and polyneuropathy (a disorder caused by the buildup of abnormal protein) … https://www.regmedinvestors.com/articles/11975
- NTLA stock rocketed 50.2% to 133.43. Shares of its partner, Regeneron Pharmaceuticals (REGN), slipped 1.4% to 542.70 after rising in earlier action. Meanwhile, shares of Crispr Therapeutics (CRSP) jumped 6.4% to 151.63. Editas Medicine (EDIT) popped 5% to 43.99 and Beam Therapeutics (BEAM) closed at 108.85, up 16%.
RegMed Investors’ (RMi) pre-open: “Q2 is coming to a close and records need to be broken as a matter of course or was it cause?” … https://www.regmedinvestors.com/articles/11974
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:
- Monday opened positive at 22/12 and 1 acquired, stayed positive at the mid-day to 18/16 and 1 acquired, closing positive at 18/15, 1 flat and 1 acquired;
The Biostage (BSTG) Chronicles: The “pump” is STILL TRYING to promote on Monday as 1,177 shares traded and the share price dripped -$0.02 to $1.23 after Friday’s 1,600 shares traded as the stock dropped -$0.10 to $1.25 after Thursday with 1,920 shares traded to “putt” the share price at $0.10 to $1.35, Wednesday’s share price popping and then dropping -$0.05 to $1.25 with 11,915 shares traded, Tuesday with the share price INFLATED +$0.09 with 4,779 shares trading and last Monday closed flat at $1.21 with 572 shares traded … WHO is buying this “zombie” as IF we didn’t know after yet another warrant execution and ever-increasing UN-REGIGISTERED share DILUTION?
Pre-open Indications: 7 HITs <Biostage (BSTG -$0.02), Global Blood Therapeutics (GBT -$3.25), Intellia Therapeutics (NTLA +$44.60), Vericel (VCEL +$0.41), Pluristem (PSTI +$0.09), Editas Medicine (EDIT +$2.11), CRISPR Therapeutics (CRSP +$9.11) and 1 MISS < Cellectis SA (CLLS +$0.64)
RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results: https://www.regmedinvestors.com/articles/11628
There are clear winners and losers
Jumping with share pricing momentum:
- Intellia Therapeutics (NTLA) - again, Crispr Therapeutics (CRSP) - again, Fate Therapeutics (FATE), Ultragenyx (RARE), Editas Medicine (EDIT) to name 5 of the 18 inclining of the 35 covered
Hammered in today’s market:
- Alnylam Pharmaceuticals (ALNY), Global Blood Therapeutics (GBT), Regenxbio (RGNX), Sage Therapeutics (SAGE), Mesoblast (MESO) - again to name 5 of the 15 declining of the 35 covered
Key metrics:
- Sector volume was HIGH with 10 of the 18-upside having higher than the 3-month average volume with LOW volume of 4 of 15-downside having higher than the 3-month average volume;
- Monday’s percentage (%) of the 18-upside were +0.10% (IONS) to +50.21% (NTLA) while the 15-downside ranges from -0.27% (FIXX) to -8.92% (GBT);
Monday’s (10 of 18) incliners: TIME to LIGHTEN a few POSITIONS
- Intellia therapeutics (NTLA +$44.60 after Friday’s +$1.99, Thursday’s +$3.25 and Wednesday’s +$4.68);
- CRISPR Therapeutics (CRSP +$9.11 after Friday’s +$4.64, Thursday’s +$7.20 and Wednesday’s +$1.48);
- Fate Therapeutics (FATE +$4.57 after Friday’s -$0.29
- Ultragenyx (RARE +$2.57 after Friday’s +$0.63);
- Editas Medicine (EDIT +$2.11 after Friday’s +$1.01, Thursday’s +$3.05, Wednesday’s +$1.41, Tuesday’s -$0.45 and Monday’s +$0.98);
- MiMedx (MDXG (+$1.10);
- Cellectis SA (CLLS +$0.64);
- ReNeuron (RENE.L +$0.50 after Friday’s -$1.00);
- Vericel (VCEL +$0.41 after Friday’s +$1.64, Thursday’s +$0.97 and Wednesday’s +$3.73);
- Bellicum Pharmaceuticals (BLCM +$0.30 after Friday’s -$0.12);
Monday’s (10 of 15) decliners:
- Alnylam Pharmaceuticals (ALNY -$9.19 after Friday’s +$1.71);
- Global Blood Therapeutics (GBT -$3.25);
- Regenxbio (RGNX -$1.50);
- Sage Therapeutics (SAGE -$1.14 after Friday’s +$1.33);
- Mesoblast (MESO -$0.45 after Friday’s -$0.27);
- Chinook Therapeutics (KDNY -$0.38 after Friday’s +$0.39);
- BioLife Solutions (BLFS -$0.19);
- Precigen (PGEN -$0.17);
- Verastem (VSTM -$0.15 after Friday’s -$0.12);
- Adverum Biotechnologies (ADVM -$0.15);
Closing 1 – Caladrius Biosciences (CLBS) and 1 -Stemline Therapeutics (STML – acquired)
Stats:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Monday, the IBB closed up +0.15% and XBI closed down -0.60%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Monday was up +0.14 points or +0.90% at 15.76
Upside volume:
- Monday: 10 out of the 18-upside had higher than the 3-month average volume;
Downside volume:
- Monday: 4 out of the 15-downside had higher than the 3-month average volume;
Percentage (%) movement/range statistics: price versus percentage …
Monday’s percentage (%) of the 18-upside were +0.10% (IONS) to +50.21% (NTLA) while the 15-downside ranges from -0.27% (FIXX) to -8.92% (GBT);
June, third month of Q2/21:
Monday closed positive with 18 advancers, 15 decliners, 1 flat and 1 acquired
Friday closed positive with 18 advancers, 13 decliners, 3 flat and 1 acquired
The BOTTOM LINE: It's end of the quarter and investors may want to take some profits and rotate out of some stem, cell and gene therapy sector equities, which has seen some multiple session highs.
On the economic front, investor attention will be focused on consumer confidence data, a private jobs report and a crucial monthly employment report due later this week.
Don’t forget there is a long holiday weekend coming (and my birthday) – many will bolt and possibly equities as well?
Reiterating, “I am STILL hearing and seeing “buy the rumor and sell the news” in my cell and gene therapy sector.
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
